No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Formycon Completes Patient Enrolment for Biosimilar Pembrolizumab Ph 1 Study
On 10 July 2025, Formycon announced that it has completed patient enrolment for its clinical study, “Dahlia”, which is comparing the pharmacokinetics, safety and tolerability of FYB206